吉西他宾联合草酸铂治疗老年晚期非小细胞肺癌

目的：观察吉西他宾（Gemcitabine）联合革酸铂（LOHP）治疗非小细胞肺癌（NSCLC）的疗效及毒性反应。方法：40例Ⅲ、Ⅳ非小细胞肺癌患者采用吉西他宾1000mg／m^2，第1、8天；草酸铂130mg／m^3，第1天，每3周为1周期，至少2周期。结果；40例患者中，CR6例，PR15例，NC14例，PD5例，总有效率为52．5％。初治组有效率66．7％。复治组有效率36．9％，两组比较，差异有显著性（P〈0．05）。结论：吉西他宾联合草酸铂治疗晚期非小细胞肺癌疗效满意，对老年及器官功能减退患者安全性高，值得临床应用。

Clinical Study on the Treatment of Non-Small-Cell Lung Cancer with Gemcitabine Plus Oxaliplatin Regimen

Objective:To evaluate the efficacy and toxicity of combination regimen of gemcitabine and oxaliplatin in treating aged advanced non-small-cell lung cancer(NSCLC).Methods: Forty patients with advanced NSCLC were treated with GL(GEM 1 000 mg/m~2,d1,d8;LOHP 130 mg/m~2,d1).The course was repeated at least 2 cycles for 3 weeks.Results:There were 6 complete response(CR),15 partial response(PR),14 no change(NC),and 5 progressive disease(PD)in this series with overall response rate of 52.5%(21/40).The response rate was 66.7%(14/21)in untreated patients and 36.9% was obtained in treated ones.A significant difference was observed between the two groups(P<0.05).The major side effects were leukemia and thrombopenia.All the side effects were tolerable.Conclusion: The GL regimen is effective and well tolerated in treating aged advanced non-small cell lung cancer and it is worthy of further clinical trial.